Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Pharma revenues up 20% in Q1
The company has reported a net income of $5.1m, or $0.12 per diluted share, against net income of $4.85m or $0.11 per diluted share, for the same period
The company has reported a net income of $5.1m, or $0.12 per diluted share, against net income of $4.85m or $0.11 per diluted share, for the same period
The new manufacturing site is a part of an expansion project within Biovest’s 35,000sqft cell culture center in Coon Rapids. The new expanded facility will manufacture Biovest’s late-stage,
The company has posted a net loss of $357,802 for the third quarter 2011, or $0.01 loss per diluted share, compared to net income of $2.1m, or $0.08
Insys uses proprietary technologies for the development of product candidates that address the clinical shortcomings of existing commercial products. Insys CEO Michael Babich said they are excited to
EX101 is a proprietary buffered effervescent dosage form of alendronate sodium administered once weekly. It is indicated to treat osteoporosis in postmenopausal women and increase bone mass in
SynCo Bio Partners is a biopharmaceutical GMP Contract Manufacturing Organization licensed for clinical and commercial GMP manufacturing of Bulk Drug Substances and Drug Products. As per the agreement,
The company expects to recruit around 1700 patients to evaluate the effectiveness of NB-001 at 72 clinical sites. The patient recruitment will be completed in 2012. NanoBio Clinical
3Me is a brand development company that operates two subsidiaries, 3Me Media and Adia Nutrition. Adia said its chewable probiotics contain 1 billion bacteria per serving and are
SCENESSE, an injectable implant formulation of the drug afamelanotide, administered every 60 days, mimics the body’s natural ability to activate melanin in the skin. In the pre-submission meeting
Cinryze received FDA approval for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. With this agreement, ViroPharma has received exclusive license to C1